{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:52Z","timestamp":1791868252365,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.diabres.2022.110183","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:33:09Z","timestamp":1669307589000},"page":"110183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Switching to a fixed-ratio combination of insulin degludec\/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study"],"prefix":"10.1016","volume":"196","author":[{"given":"Salah","family":"Abusnana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatheya","family":"Al Awadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Bashier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar Dhanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Halasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Jallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2022.110183_b0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-019-01245-3","article-title":"Clinical considerations when initiating and titrating insulin degludec\/liraglutide (IDegLira) in people with type 2 diabetes","volume":"80","author":"Harris","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.diabres.2022.110183_b0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","article-title":"Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review","volume":"7","author":"Ostawal","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2022.110183_b0015","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl. 1):S73\u201384. doi: 10.2337\/dc21-S006.","DOI":"10.2337\/dc21-S006"},{"issue":"15","key":"10.1016\/j.diabres.2022.110183_b0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2022.110183_b0025","doi-asserted-by":"crossref","unstructured":"Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?. Diabetol Metab Syndr 2018;10:26.https:\/\/doi.org\/10.1186\/s13098-018-0327-4.","DOI":"10.1186\/s13098-018-0327-4"},{"issue":"3","key":"10.1016\/j.diabres.2022.110183_b0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pcd.2015.12.005","article-title":"IDegLira: redefining insulin optimisation using a single injection in patients with type 2 diabetes","volume":"10","author":"Hughes","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabres.2022.110183_b0035","doi-asserted-by":"crossref","unstructured":"Davies MJ, D'Alessio DA., Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41(12):2669\u20132701. https:\/\/doi.org\/10.2337\/dci18-0033.","DOI":"10.2337\/dci18-0033"},{"key":"10.1016\/j.diabres.2022.110183_b0040","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl. 1):S111\u201324. https:\/\/doi.org\/10.2337\/dc21-S009.","DOI":"10.2337\/dc21-S009"},{"key":"10.1016\/j.diabres.2022.110183_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108466","article-title":"Impact of provision of optimum diabetes care on the safety of fasting in Ramadan in adult and adolescent patients with type 1 diabetes mellitus","volume":"169","author":"Alawadi","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2022.110183_b0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s13300-021-01012-2","article-title":"Delphi-based consensus on treatment intensification in type 2 diabetes subjects failing basal insulin supported oral treatment: focus on basal insulin + GLP-1 receptor agonist combination therapies","volume":"12","author":"Fadini","year":"2021","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.diabres.2022.110183_b0055","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2017.1288715","article-title":"Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes","volume":"16","author":"Vedtofte","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.diabres.2022.110183_b0060","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-015-0448-0","article-title":"Insulin degludec\/liraglutide: a review in type 2 diabetes","volume":"75","author":"Greig","year":"2015","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.diabres.2022.110183_b0065","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2022.110183_b0070","unstructured":"Xultophy [prescribing information]. 2019. https:\/\/www.novo-pi.com\/xultophy10036.pdf [accessed 15 December 2021]."},{"key":"10.1016\/j.diabres.2022.110183_b0075","unstructured":"Xultophy [summary of product characteristics]. 2020. https:\/\/www.medicines.org.uk\/emc\/medicine\/29493. [accessed 15 December 2021]."},{"issue":"11","key":"10.1016\/j.diabres.2022.110183_b0080","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","article-title":"Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)","volume":"37","author":"Buse","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2022.110183_b0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.diabres.2022.110183_b0090","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2022.110183_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.diabres.2022.110183_b0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dme.13256","article-title":"Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-na\u00efve people with type 2 diabetes: the DUAL IV trial","volume":"34","author":"Rodbard","year":"2017","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.diabres.2022.110183_b0105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/dom.12892","article-title":"Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial","volume":"19","author":"Harris","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2022.110183_b0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/dom.13957","article-title":"A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec\/liraglutide versus insulin glargine 100 units\/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice","volume":"22","author":"Sesti","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2022.110183_b0115","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/dom.13666","article-title":"Superior efficacy of insulin degludec\/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes","volume":"21","author":"Philis-Tsimikas","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2022.110183_b0120","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/dom.13182","article-title":"Use and effectiveness of a fixed-ratio combination of insulin degludec\/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study","volume":"20","author":"Price","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabres.2022.110183_b0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13300-017-0234-y","article-title":"Glycemic control in a real-life setting in patients with type 2 diabetes treated with IDegLira at a single Swiss center","volume":"8","author":"Sofra","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.110183_b0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13300-019-00725-9","article-title":"Metabolic control and adherence to therapy in type 2 diabetes mellitus patients using IDegLira in a real-world setting","volume":"11","author":"Melzer-Cohen","year":"2020","journal-title":"Diabetes Ther"},{"issue":"7","key":"10.1016\/j.diabres.2022.110183_b0135","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s13300-020-00850-w","article-title":"Glycemic control among patients newly prescribed IDegLira across prior therapy group in US real-world practice","volume":"11","author":"Egede","year":"2020","journal-title":"Diabetes Ther"},{"issue":"20","key":"10.1016\/j.diabres.2022.110183_b0140","first-page":"10671","article-title":"IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience","volume":"24","author":"Di Loreto","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.diabres.2022.110183_b0145","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s13300-020-00872-4","article-title":"Persistence with IDegLira in patients in clinical practice: a nationwide observational study in Sweden","volume":"11","author":"Eliasson","year":"2020","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.diabres.2022.110183_b0150","first-page":"923","article-title":"Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy","volume":"25","author":"Persano","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.diabres.2022.110183_b0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13300-020-00945-4","article-title":"Real-world evaluation of glycemic outcomes and extra-glycemic parameters in diabetic patients treated with the combined formulation degludec-liraglutide (IDegLira)","volume":"12","author":"Zenari","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2022.110183_b0160","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th edn 2021. https:\/\/www.diabetesatlas.org. [accessed 4 January 2022]."},{"key":"10.1016\/j.diabres.2022.110183_b0165","unstructured":"World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2004. https:\/\/www.wma.net\/wp-content\/uploads\/2018\/07\/DoH-Oct2004.pdf. [accessed 10 March 2022]."},{"key":"10.1016\/j.diabres.2022.110183_b0170","unstructured":"International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). 2015. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/. [accessed 10 March 2022]."},{"issue":"1","key":"10.1016\/j.diabres.2022.110183_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000506508","article-title":"Emirates Diabetes Society Consensus guidelines for the management of type 2 diabetes mellitus \u2013 2020","volume":"26","author":"Alawadi","year":"2020","journal-title":"Dubai Diabetes Endocrinol J"},{"issue":"9","key":"10.1016\/j.diabres.2022.110183_b0180","first-page":"681","article-title":"Early and tight glycaemic control - the key to managing type 2 diabetes","volume":"41","author":"Deed","year":"2012","journal-title":"Aust Fam Physician"},{"issue":"1","key":"10.1016\/j.diabres.2022.110183_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000531","article-title":"Physicians' real-world experience with IDegLira: results of a European survey","volume":"6","author":"Drummond","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"10.1016\/j.diabres.2022.110183_b0190","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1210\/jc.2019-01021","article-title":"Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study","volume":"104","author":"Fadini","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:24:26Z","timestamp":1759173866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722009974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":38,"alternative-id":["S0168822722009974"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110183","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to a fixed-ratio combination of insulin degludec\/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110183"}}